Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI) -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (1266)	10/11/2002 8:08:09 AM
From: Al Collard	Respond to of 1321

QLT and Novartis Ophthalmics launch phase III program to treat skin cancer newswire.ca

To: Ian@SI who wrote (1266)	10/21/2002 4:47:31 PM
From: Brasco One	Read Replies (1) \| Respond to of 1321

lol if you are still long! major lol!!

To: Ian@SI who wrote (1266)	5/12/2003 4:11:07 PM
From: tuck	Read Replies (1) \| Respond to of 1321

This looks pretty bad if Visudyne can't pull the cart. >>VANCOUVER, May 12 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI - News; TSX: QLT - News) announced today that it will stop its current Phase III tariquidar trials in non-small cell lung cancer. This decision was made by QLT following a recommendation by the Independent Data Safety Monitoring Committee (DSMC) who completed the unblinded review of the data for both ongoing trials in this indication. Members of the Company's clinical development team will now be unblinded so that they have opportunity to review all of the data and can make informed decisions about plans for future development of tariquidar. Data from the 304 patients already enrolled in these studies represents the largest collection of efficacy and safety data from randomized, placebo-controlled studies of a third generation P-gp inhibitor and will offer valuable insight into the potential for tariquidar in this or other indications. It is QLT's intention to exploit the value of this database and make planning decisions for tariquidar after a thorough analysis of such data. QLT expects that there will be savings associated with stopping the trial, and will update what that potential impact might be after a careful review of the interim analysis. The DSMC is an independent panel of experts who are not participating in the studies. The primary responsibility of the DSMC is to oversee the studies and safeguard the interests of current and future participants in these trials. About Tariquidar Enrollment began in June 2002, for the two phase III clinical trials using tariquidar as an adjunctive treatment in combination with first-line chemotherapy for non-small cell lung cancer (NSCLC) patients. Approximately 1000 patients were to be enrolled in two randomized, multi-centered, placebo- controlled trials using tariquidar in combination with two of the most commonly used chemotherapy regimens (paclitaxel plus carboplatin or vinorelbine alone). The trials were conducted at roughly 100 centers located throughout North America and Europe, and were designed to demonstrate the ability of tariquidar to enhance the efficacy of chemotherapy agents. This occurs by preventing or overcoming resistance due to overexpression of P-glycoprotein (P-gp), a membrane protein that pumps chemotherapeutic agents out of cancer cells. Tariquidar was in-licensed from Xenova Group plc (NASDAQ NM: XNVA - News; London Stock Exchange: XEN - News) for the development and marketing rights in North America in August 2001. QLT Inc. (NASDAQ: QLTI - News; TSX: QLT - News) is a global pharmaceutical company specializing in the discovery, development and commercialization of innovative therapies to treat cancer, eye diseases and niche areas for which treatments can be marketed by a specialty sales force. Combining expertise in ophthalmology, oncology and photodynamic therapy, QLT has commercialized two products to date, including Visudyne therapy, which is the most successfully launched ophthalmology product ever. For more information, visit our web site at www.qltinc.com. Conference Call Information QLT Inc. will hold an analyst and institutional investor conference call to discuss this item on Monday, May 12 at 5:00 p.m. EST (2:00 p.m. PST) via telephone at (416) 695-5806. The call will be broadcast live via the Internet at www.qltinc.com. A replay of the call will be available via the Internet and also via telephone at (416) 695-5800, access code 1422099. QLT Inc.: Media Contact: Therese Hayes Anna Wright (James Hoggan) Telephone: 604-707-7000 or 1-800-663-5486 Telephone: 604-742-4261 Fax: 604-707-7001<< snip Cheers, Tuck